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Abstract
Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) share many features and both arise from CD5+ B-cells, their distinction is critical as
MCL is a much more aggressive neoplasm. Rarely, composite MCL and CLL/SLL have been
reported. Little is known, about the nature of these cases and in particular the clonal relationship
of the two lymphomas. Eleven composite MCL and CLL/SLL cases were identified. The clinical,
morphologic and immunophenotypic features of the MCL and CLL/SLL were characterized.
Immunoglobulin heavy chain (IGH) gene analysis was performed on microdissected MCL and
CLL/SLL components to assess their clonal relationship. Ten patients had lymphadenopathy, and
7 patients had bone marrow involvement. The MCL component had the following growth
patterns: in situ (n=1), mantle zone (n=3), nodular and diffuse (n=3), diffuse (n=3), and interstitial
in the bone marrow (the only patient without lymphadenopathy) (n=1); 6 MCL had blastoid or
pleomorphic and 5 classical cytologic features. The CLL/SLL component was internodular (n=9)
or diffuse (n=2). All MCL were CD5+ and cyclin D1+ with t(11;14) translocation. All CLL/SLL
were CD5+, CD23+ and negative for cyclin D1 or t(11;14). IGH gene analysis showed that the
MCL and CLL/SLL components displayed different sized fragments, indicating that the MCL and
CLL/SLL are likely derived from different neoplastic B-cell clones. The lack of a clonal
relationship between the MCL and CLL/SLL components suggests that the MCL and CLL/SLL
represent distinct disease processes and do not share a common progenitor B-cell.
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Mantle cell lymphoma (MCL) accounts for approximately 6% of all B-cell lymphomas in
Western countries [1,2]. The incidence rate is about 0.2–0.3 cases per 100,000 person-years,
and the median age at diagnosis is about 60 years. Patients usually present with
lymphadenopathy and commonly have involvement of the bone marrow, liver, spleen and
gastrointestinal tract. Morphologically, typical cases of MCL are composed of a monotonous
population of small often angulated B-cells that express CD5 and grow with a diffuse,
nodular, or mantle zone pattern. MCL is usually characterized by the presence of t(11;14)
(q13;q32), which juxtaposes the cyclin D1 gene with the immunoglobulin heavy chain gene
(IGH) locus and results in overexpression of cyclin D1 [3]. MCL most often arises from a
CD5+ B-cell without mutations in the IGH variable regions (IGHV), although a subset of
MCL cases have somatically mutated IGHV [4–9].
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most
common adult blood cancer in Western countries and accounts for approximately 30% of all
lymphoid neoplasms and 12% of nodal lymphomas [1,2]. The incidence rate is about 2–6
cases per 100,000 person-years and the median age at diagnosis is about 65 years [1].
Morphologically, lymph nodes usually demonstrate diffuse architectural effacement by
small lymphocytes with vague, pale proliferation centers that also include paraimmunoblasts
and prolymphocytes; occasionally CLL/SLL has a nodular appearance with pseudofollicles
and sometimes the nodal spread is parafollicular/internodular. The predominant tumor cell
type in CLL/SLL is a small CD5+, CD23+ B-lymphocyte.
Composite lymphoma is the term used to describe a single anatomic site involved by two
distinct types of lymphoma. Traditionally, the two components of composite lymphoma
have been thought to not be clonally related, although microdissection and molecular
analysis has shown that morphologically disparate lymphomas can be clonally related or
arise from a common progenitor cell at the molecular level [10–13]. A wide variety of
lymphoma types have been described in composite lymphomas, however, the combination
of MCL and CLL/SLL is uncommon and very few molecular studies have been performed
on this rare form of composite lymphoma [14;15].
Here we report a series of 11 cases of composite lymphoma showing MCL and CLL/SLL
components involving the same biopsy specimen. We describe clinical features,
immunophenotype and, when possible, the results of IGH gene rearrangement analysis of
each component to assess the clonal relationship of the MCL and CLL/SLL components.
Materials and Methods
Case Selection
Cases of composite MCL and CLL/SLL were identified through a multi-institutional
collaboration involving five medical centers. All cases were reviewed by a group of
hematopathologists (all primary center pathologists and KHY), and the diagnoses were
confirmed on the basis of WHO classification criteria [2]. The current study was approved
by each of the participating center Institutional Review Boards, and the overall collaborative
study was approved by the Institutional Review Board at The University of Texas MD
Anderson Cancer Center in Houston, Texas.
Histology and immunohistochemistry
All specimens were fixed in 10% neutral buffered formalin, embedded in paraffin, and 4 µm
sections were cut and stained with hematoxylin and eosin for histological evaluation.
Immunohistochemical staining was performed using formalin-fixed, paraffin-embedded
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tissue sections. Briefly, tissue sections were deparaffinized in xylene, rehydrated in graded
alcohols, and endogenous peroxidase was blocked with 3% hydrogen peroxide. For antigen
retrieval, tissue sections were immersed in citrate buffer (pH 6.0) as appropriate for each
antibody used. After the sections were rinsed with phosphate-buffered saline,
immunohistochemical analysis was performed for purposes of the present study using
antibodies against CD3, CD10, kappa, lambda, IgA, IgG, IgM, and IgD (PS1, 56C6, 2F3.2
clones, respectively, polyclonal light and heavy chains) (Ventana, Tucson, Arizona); CD5
(4C7 clone, Novocastra, Newcastle-on-Tyne, UK); CD20 (L26 clone) and BCL6 (PG-B6p
clone) (Dako, Carpinteria, California), CD23 (BU38 clone) ZAP-70 (Binding Site,
Birmingham, UK), and cyclin D1 (SP4 clone, Neomarkers, Freemont, California). These
stains were performed on an automated immunostainer (Benchmark XT from Ventana/
Roche, Tucson, Arizona) using a streptavidin-biotin peroxidase detection system.
Flow Cytometry Studies
Lymph node and bone marrow aspirate specimens were processed according to established
procedures. Briefly, mononuclear cells were isolated from the lymph node or bone marrow
samples by Ficoll-Hypaque density-gradient centrifugation (Accu-Prep, Accurate Chemical,
Westbury, New York). Contaminating red blood cells were removed by hypotonic lysis with
0.9% sodium chloride. Isolated cells were washed with phosphate-buffered saline (PBS) and
resuspended in RPMI 1640 (Life Technologies, Grand Island, New York) supplemented
with 1 mol/L of Hepes buffer, L-glutamine, penicillin, streptomycin, and 10% fetal calf
serum. The separated cells were counted by using the trypan blue exclusion method, divided
into aliquots, and placed in 5 mL plastic tubes at a concentration of 2 × 105 cells per tube.
Cells were incubated with antibody cocktails in 200 µL of cold PBS with 0.5% bovine
serum albumin for 30 minutes at 4°C. Antibodies specific for CD3, CD5, CD10, CD19,
CD20, CD22, CD23, CD38, CD43, CD79a, kappa and lambda light chains, were used
according to manufacturer’s recommendations. After incubation, the cells were washed with
PBS, and the cell pellets were resuspended in 1% paraformaldehyde in PBS. Data were
collected on a Beckman Coulter FC500 flow cytometer (Beckman Coulter, Miami, FL)
using Beckman Coulter Cytomics RXP software (Applied Cytometry Systems, Dinnington,
UK), and list mode files were acquired for off-line analysis.
FISH Analysis
To detect the t(11;14)(q13;q32) formalin-fixed, paraffin-embedded tissue sections were
analyzed via interphase FISH analysis using the commercially available LSI IgH/CCND1
XT Dual-Color, Dual-Fusion Translocation Probe (Abbott/Vysis, Des Plaines, Illinois) as
described [16].
Immunoglobulin heavy chain analysis
Genomic DNA was extracted using a Genovison extraction kit (Qiagen, Valencia,
California) from separately microdissected MCL and CLL/SLL components. Positively
stained cells from uncovered and un-counterstained tissue slides stained for either cyclin D1
(MCL component) or CD23 (CLL/SLL component) were microdissected as described [16].
Polymerase chain reaction (PCR) based analysis for IGH gene rearrangements was
performed utilizing consensus FR1, FR3 and J primers, as previously described [17]. The
PCR products were examined using a high resolution fragment length analyzer (ABI 310
Genetic Analyzer, Applied Biosystems/Life Technologies, Carlsbad, California). DNA from
normal polyclonal B-cell populations produced a bell-shaped curve of amplicon products
(Gaussian distribution), and was used as control. Monoclonal gene rearrangements were
identified as prominent, single-sized amplification products; the base pair length was
recorded for each microdissected fraction. A shift of the PCR products of more than one bp
between the cases was considered to indicate a clonally unrelated event.
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The clinical information is summarized in Table 1. There were 10 male and 1 female
patients with a median age of 73 years (range, 55 to 80 years). Ten patients had
lymphadenopathy and 1 patient presented with only bone marrow involvement. Four
patients with lymphadenopathy also had bone marrow involvement. Eight patients had
advanced disease at diagnosis, including 1 stage III and 7 stage IV. Three patients presented
with stage II disease. Peripheral blood lymphocytosis (5.6 – 8.7 × 109/L) was present in 4 of
8 patients with a complete blood count and peripheral bloods smear available for review.
Five patients died of disease, 4 patients were alive at the time of the manuscript preparation
with a follow-up time between 1 and 67 months (mean 29 months), and 2 patients are lost to
follow-up. The median survival was 42 months (95% CI: 27–56).
Histology, immunohistochemistry and flow cytometry analyses
Ten biopsy specimens were obtained from lymph nodes and bone marrow was biopsied in 5
patients (Tables 1–2). All biopsy specimens were reviewed by at least three
hematopathologists [KHY, AT and the primary contributing pathologists], and were
classified as composite lymphoma. The MCL component had blastoid or pleomorphic
cytologic features in 6 patients and classical features in 5 patients (Figures 1–7,
Supplemental Figure for case-7, Table 2). The pattern of the MCL component was in situ
(n=1), mantlezone (n=3), nodular and diffuse (n=3), diffuse (n=3), and in the bone marrow
only case, interstitial (n=1). The accompanying CLL/SLL components were parafollicular/
internodular (n=9) or diffuse (n=2).
In all cases, both the MCL and CLL/SLL components had a classical phenotype. The MCL
component was CD5+, cyclin D1+, and CD23−. The CLL/SLL component was CD5+,
CD23+, and cyclin D1−. IgD was expressed in the MCL component of all cases (Table 3,
and Figures 1–7), as well as in the CLL/SLL component in 5 cases, although at a weaker
intensity in some cases. The light chain expression was assessable in 9/11 cases and seven
(cases 1, 2, 3, 5, 7, 8 and 10) showed different clonal light chain restriction in the CLL/SLL
and MCL populations. ZAP70 was negative in all cases of MCL and was positive in areas
densely involved by CLL/SLL in 30–100% of cells in 7 cases.
IGH Analysis by PCR
The IGH results obtained from microdissected cyclin D1+ MCL cells or CD23+ CLL/SLL
cells (Figure 8) revealed that out of the 7 cases with sufficient material for analysis 6 had a
monoclonal peak in the respective microdissected components. In all 6 cases, the MCL and
CLL/SLL cells displayed differently sized amplicons, indicating that the MCL and CLL/
SLL components were derived from different B-cell clones (Table 3). Signals indicating at
least two amplicons of different sizes (one the size of the other microdissected component,
and another of a different size) in one of the microdissected components were identifiable in
5 cases (5 in CLL/SLL components and 3 in MCL components) indicated that, despite
microdissection, isolated tumor cells of either neoplastic components had “contaminated”
the specimens. Nevertheless, in all cases except 1, the relative peak heights as well as the
amplicon sizes and the concurrent detection of the t(11;14) with the chosen multiplex PCR
design (detectable in all 5 in all MCL components) allowed for reliable result interpretation.
In case 5, the fragment length of 118 bp was the same in both components, but since the
Supplemental Figure (Case 7): Imunophenotypic features of a composite case of MCL and CLL/SLL. (A) MCL component with
expression of CD5, CD19, bright CD20, CD22, CD38, and bright monotypic kappa light chains. (B) CLL/SLL component with
expression of CD5, CD19, dim CD20, CD22, CD23, CD38, and dim monotypic lambda light chains.
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PCR was designed to detect the t(11;14) as well, and this failed in the cyclin D1+
microdissected fraction due to technical reason, poor quality of extracted DNA or due to
“contamination” with CLL/SLL cells, a clonal relationship could not be regarded proven in
this case. However, FISH confirmed the presence of t(11;14) translocation in the MCL of
case 5, but not in the CLL/SLL component.
Repeated IGH results obtained from microdissected cyclin D1+ MCL cells or CD23+ CLL/
SLL cells from cases 1, 2 and 7 achieved similar results. However, purified DNA peak
products from PCR agarose gel failed in IGH sequencing analysis.
Discussion
We present the largest series of composite lymphomas consisting of MCL and CLL/SLL. In
our literature review, we found only four previous case reports in the literature that
presented similar observations [14,15,18,19]. Importantly, none of the MCL components in
these four cases were shown to be clonally related to the CLL/SLL component. These
findings support our results, since the IGH rearrangements amplified were, yet limited by
technical difficulties of probable “contamination” of the microdissection specimens by each
other component of the composite lymphoma, of different size in the MCL and CLL/SLL
components in 5/6 analyzed cases. These observations are further supported by the different
light chain restriction of both components in 3/5 informative cases. These cases can be
therefore considered as bona fide examples of composite lymphoma consisting clonally
unrelated MCL and CLL/SLL. This result is perhaps surprising, since MCL and CLL/SLL
share morphological and immunophenotypic characteristics and are thought to arise from
CD5+ B-cells that can undergo somatic mutation of the IGHV genes [4–9]. Nevertheless, the
unanimous results in a total of 9 cases analyzed (our 5 and those reported in the literature),
makes a strong case for a lack of a clonal relationship in cases of composite MCL and CLL/
SLL.
Our actual observation of lacking clonal relationship between MCL and CLL/SLL is clearly
different to what we recently observed in MCL with a plasma cell component [16], showing
evidently a clonal relationship in a subset of the cases, which we supposed might be due to a
retained MCL propensity to “mature” towards neoplastic plasma cells in such rare occasions
rather than representing composite neoplasms sensu strictu. Along with the retained ability
to undergo somatic IGHV hypermutations, the observed plasmacytic “maturation” of MCL
points towards some plasticity of the latter. Nevertheless, our present data support mutually
exclusive MCL or CLL/SLL lymphomagenic pathways of naïve CD5+ B-cells; MCL being
tightly linked to cell cycle dysregulation through cyclin D1 overexpression and
accumulation of additional genomic aberrations to inactivate DNA damage response
pathways, whereas CLL/SLL being more linked to apoptosis arrest and NF-κB activation
[20,21].
The question remains whether the simultaneous presence of MCL and CLL/SLL is simply
co-incidence or can be attributed to a common biological denominator. Importantly, patients
with a history of CLL/SLL have a two-fold increased risk of developing other malignancies
such as skin, prostate, breast and colon cancer, as well as a 10-fold increased risk of
developing other lymphomas, including Hodgkin lymphoma [22]. This risk in CLL/SLL
patients could be explained by environmental and/or genetic factors [23–28], increasing the
individual susceptibility for lymphomagenesis.
From a diagnostic point of view, the results of this study show that it is essential in “small
B-cell lymphomas” to perform immunohistochemical studies for CD5, CD23 and cyclin D1
in order to detect morphologically unexpected co-incidental MCL (including in situ MCL)
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in a CLL/SLL case or vice versa. The detection of a second, clonally unrelated lymphoma
may be helpful for therapeutic decisions or prognostic stratification.
In summary, we have reported 11 cases of composite MCL and CLL/SLL with assessment
of the clonal relationship of the two components. Patients with composite MCL and CLL/
SLL usually present with lymphadenopathy, high stage disease, and have a poor prognosis.
In at least 7 cases we report, as well as in 4 cases reported by others, the MCL and CLL/SLL
components were not clonally related as manifested by different immunoglobulin light chain
expression or other immunophenotypic features, variable IGH rearrangements amplified,
t(11;14) translocation, and unique morphologic features.
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Histologic and immunophenotypic features of a composite case of MCL and CLL/SLL. (A
and B) Nodular pattern of atypical small lymphoid cells with a nodular pattern (H&E
staining; original magnification: 20X and 100X). (C) Positive CD20 staining of atypical
small lymphoid cells in both the internodular and nodular areas (immunoperoxidase
staining; original magnification: 40X). (D) Cyclin D1 staining of atypical small lymphoid
cells in the nodular area (immunoperoxidase staining; original magnification: 40X). (E and
F) Atypical small lymphoid cells in the internodular area (H&E staining; original
magnification: 20X and 100X). (G) Weak CD20 staining of atypical small lymphoid cells in
the internodular area (immunoperoxidase staining; original magnification: 40X). (H)
Negative cyclin D1 staining of atypical small lymphoid cells in the internodular area
(immunoperoxidase staining; original magnification: 40X). (I) CD3 staining of normal small
T-cells in the internodular area (immunoperoxidase staining; original magnification: 20X).
(J) CD5 staining of atypical small lymphoid cells in both the internodular and nodular areas
(immunoperoxidase staining; original magnification: 20X). (K) Ki-67 staining of a relatively
high proliferation index in the nodular area (immunoperoxidase staining; original
magnification: 40X).
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Histologic and immunophenotypic features of a composite case of MCL and CLL/SLL. (A)
Two irregular patterns of atypical small lymphoid infiltration in an effaced lymph node; one
is nodular, and the other is diffuse (H&E staining; original magnification: 20X). (B) CD20
staining of atypical small lymphoid cells in both nodular and diffuse areas
(immunoperoxidase staining; original magnification: 20X). (C) Atypical MCL infiltration
(H&E staining; original magnification: 100X). (D) Atypical SLL infiltration (H&E staining;
original magnification: 40X). (E) CD3 staining of normal small T-cells in the internodular
area (immunoperoxidase staining; original magnification: 20X). (F) CD5 staining of atypical
small lymphoid cells in both the internodular and nodular areas (immunoperoxidase
staining; original magnification: 20X). (G) Cyclin D1 staining of atypical small lymphoid
cells in the MCL area (immunoperoxidase staining; original magnification: 20X). (H) Ki-67
staining of a high proliferation index in the MCL area (immunoperoxidase staining; original
magnification: 20X). (I) Nodular pattern of atypical lymphoid cells with expanded mantle
zone and internodular areas (H&E staining; original magnification: 20X). (J) Differential
CD20 staining of atypical lymphoid cells in the nodular and internodular areas
(immunoperoxidase staining; original magnification: 20X). (K) CD3 staining of small T-
cells in the internodular areas (immunoperoxidase staining; original magnification: 20X).
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(L) Weak CD5 staining of atypical lymphoid cells in the nodular and internodular areas
(immunoperoxidase staining; original magnification: 20X). (M) Cyclin D1 staining of
atypical lymphoid cells in the expanded mantle zone and internodular areas with a focal
negative area of SLL (immunoperoxidase staining; original magnification: 20X).
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Histologic and immunophenotypic features of a composite case of MCL and CLL/SLL. (A)
Nodular pattern of atypical small lymphoid infiltration in an effaced lymph node (H&E
staining; original magnification: 20X). (B) Atypical SLL infiltration (H&E staining; original
magnification: 100X). (C) Atypical MCL infiltration (H&E staining; original magnification:
100X). (D) CD20 staining of atypical small lymphoid cells in both the internodular and
nodular areas (immunoperoxidase staining; original magnification: 20X). (E) CD5 staining
of atypical lymphoid cells in the nodular and internodular areas (immunoperoxidase
staining; original magnification: 20X). (F) CD23 staining of atypical lymphoid cells in the
internodular SLL areas (immunoperoxidase staining; original magnification: 20X). (G)
Cyclin D1 staining of atypical lymphoid cells in the mantle zone and nodular areas with a
focal negative area of SLL (immunoperoxidase staining; original magnification: 20X). (H)
Ki-67 staining of a high proliferation index in the MCL area (immunoperoxidase staining;
original magnification: 20X). (I) Nodular pattern of atypical small lymphoid infiltration in
an effaced lymph node (H&E staining; original magnification: 20X). (J) Atypical lymphoid
infiltration (H&E staining; original magnification: 40X). (K) Atypical MCL infiltration
(H&E staining; original magnification: 100X). (L) CD20 staining of atypical small
lymphoid cells in both the internodular and nodular areas (immunoperoxidase staining;
original magnification: 20X). (M) CD5 staining of atypical lymphoid cells in the nodular
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and internodular areas (immunoperoxidase staining; original magnification: 20X). (N) CD23
staining of atypical lymphoid cells within the nodules of SLL areas (immunoperoxidase
staining; original magnification: 20X). (O) Cyclin D1 staining of atypical lymphoid cells in
the mantle zone and nodular areas with a focal negative area of SLL (immunoperoxidase
staining; original magnification: 20X). (P) Ki-67 staining of a high proliferation index in the
mantle zone area (immunoperoxidase staining; original magnification: 20X).
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Histologic and immunophenotypic features of a composite case of MCL and CLL/SLL. (A)
Two irregular patterns of atypical small lymphoid infiltration in an effaced lymph node; one
is nodular with intermediate-sized cells, and the other is diffuse with smallsized cells (H&E
staining; original magnification: 20X). (B) Atypical SLL infiltration (H&E staining; original
magnification: 100X). (C) Atypical MCL infiltration (H&E staining; original magnification:
100X). (D) CD20 staining of atypical small lymphoid cells in both nodular and diffuse areas
(immunoperoxidase staining; original magnification: 20X). (E) CD5 staining of atypical
small lymphoid cells in both the internodular and nodular areas (immunoperoxidase
staining; original magnification: 20X). (F) CD23 staining of SLL cells in the nodular area
(immunoperoxidase staining; original magnification: 20X). (G) Cyclin D1 staining of
atypical small lymphoid cells in the MCL area (immunoperoxidase staining; original
magnification: 20X). (H) Ki-67 staining of a high proliferation index in the SLL area
(immunoperoxidase staining; original magnification: 20X).
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Histologic and immunophenotypic features of a composite case of MCL and CLL/SLL. (A)
A nodular pattern of atypical small lymphoid infiltration in an effaced lymph node (H&E
staining; original magnification: 20X). (B) Atypical mantle-zone growth pattern (H&E
staining; original magnification: 100X). (C) Atypical small lymphoid infiltration in the
internodular area (H&E staining; original magnification: 100X). (D) CD20 staining of
atypical lymphoid nodules (immunoperoxidase staining; original magnification: 40X). (E)
Cyclin D1 staining of atypical small lymphoid cells in the mantle zone (immunoperoxidase
staining; original magnification: 40X). (F) CD23 staining of SLL cells in the nodular area
(immunoperoxidase staining; original magnification: 20X). (G) CD5 staining of atypical
small lymphoid cells in the internodular areas and a few small T-cells within the follicles
(immunoperoxidase staining; original magnification: 40X). (H) Ki-67 staining of a high
proliferation index in the reactive follicles (immunoperoxidase staining; original
magnification: 40X).
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Histologic and immunophenotypic features of a composite case of MCL and CLL/SLL. (A-
C) A diffuse pattern of atypical lymphoid infiltration (H&E staining; original magnification:
20X and 100X). (D) CD20 staining of atypical lymphoid cells (immunoperoxidase staining;
original magnification: 20X). (E) CD3 staining of normal small T-cells (immunoperoxidase
staining; original magnification: 20X). (F) CD5 staining of atypical small lymphoid cells
(immunoperoxidase staining; original magnification: 20X). (G) Cyclin D1 staining of
atypical small lymphoid cells (immunoperoxidase staining; original magnification: 20X).
(H) Ki-67 staining of a low proliferation index in the MCL area (immunoperoxidase
staining; original magnification: 20X). (I) Bone marrow aspirate smear showing a few
scattered atypical lymphoid cells with a clumped chromatin pattern. Flow cytometry
revealed that these atypical lymphoid cells were positive for CD5, dim CD20, CD23, and
monotypic kappa light chains, whereas cyclin D1 staining was negative based on the
immunostaining of the bone marrow biopsy (data not shown).
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Histologic and immunophenotypic features of two composite cases of MCL and CLL/SLL.
(A and B) A diffuse and interstitial pattern of small atypical lymphoid infiltration (H&E
staining; original magnification: 20X and 100X). (C and D) A nodular and interstitial
pattern of atypical lymphoid infiltration (H&E staining; original magnification: 20X and
100X). (E) Flow cytometry revealed two clonal populations of small B-cells: a predominant
population of B-cells expressed CD5, CD19, dim CD20, CD23, and dim monotypic kappa
light chains, and a small population of bright CD19/CD20/CD79a-positive B-cells expressed
monotypic lambda light chains. Both populations were positive for CD5 and negative for
CD10.
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IGH gene rearrangement analysis of six composite cases of MCL and CLL/SLL revealed
that the two lymphoid populations were clonally unrelated in five cases. Similar but also
distinct clonal peaks are seen in the separate PCR runs of both components in cases 1, 2, 6
and 7. Since biclonal (biallelic) rearrangements in one, especially in the SLL, component of
these composite cases are very unprobable, this indicates that, despite microdissection,
isolated tumor cells particularly of the MCL component had “contaminated” the specimens.
In case 6 the SLL component presents with peaks at 138 and 141 bp, which is rather
attributable to a typical PCR anomaly - 3bp increment of the same IGH gene PCR product
because of in frame code - than to a biallelic rearrangement. In case 4 there are 3 peaks, with
a considerable decrease of the relative peak size of the 111bp component in the CD23+
microdissected cells, indicating that this peak more probably belongs to the MCL
component. For case 5 see explanations in the text. For clarity only larges peaks’ sizes are
indicated.
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Table 2
Morphologic and cytologic features of composite mantle cell lymphoma and chronic lymphocytic leukemia/
small lymphocytic lymphoma
Case Morphological CLL/SLL pattern Morphological MCL pattern Morphological MCL subtype
1 Internodular Nodular and diffuse Blastoid
2 Internodular Nodular and diffuse Blastoid
3 Internodular In Situ Small lymphocytic
4 Internodular Mantle zone Small lymphocytic
5 Internodular Nodular and diffuse Blastoid
6 Diffuse Focal, Patchy Blastoid
7 Nodular Mantle zone Small lymphocytic
8 Internodular Diffuse Blastoid
9 Internodular Diffuse Small lymphocytic
10 Internodular Diffuse Blastoid
11 Nodular Interstitial Small lymphocytic
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